Skyrizi from AbbVie Inc. - psoriasis dosing now stretches to 52 weeks

Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-29, 08:22. Details in the imprint.

The Skyrizi syringe from AbbVie Inc. sits cool and small in the palm, a clear liquid that for many plaque psoriasis patients has become part of a quiet ritual every few months. One injection, then weeks of smoother skin and fewer stares on the train.

How Skyrizi is given

Skyrizi is an injectable monoclonal antibody targeting the interleukin-23 pathway and is approved for moderate to severe plaque psoriasis in adults. After two starter doses at week 0 and week 4, patients move to a maintenance schedule of just one injection every 12 weeks.

For psoriasis patients used to frequent biologic infusions, that 12-week rhythm feels like a different pace of life. Dermatologist Dr. Laura Ferris has described IL-23 inhibitors such as risankizumab, the active ingredient in Skyrizi, as offering a notably “convenient” dosing profile for long-term control.

What the data show on skin clearance

In pivotal Phase 3 trials, a high share of Skyrizi patients reached PASI 90, meaning at least 90 percent improvement in psoriasis severity, and many maintained this response through 52 weeks. The product information highlights sustained efficacy and a safety profile broadly consistent with other biologics in its class.

Where Skyrizi fits in AbbVie’s line-up

AbbVie positions Skyrizi as a core immunology pillar alongside Rinvoq, with ambitions to reach multibillion-dollar annual sales globally. In recent presentations, CEO Richard A. Gonzalez has repeatedly pointed to Skyrizi as a driver of “durable” revenue growth as legacy products like Humira face biosimilar competition.

Beyond plaque psoriasis, Skyrizi now has approvals in psoriatic arthritis and Crohn’s disease, giving the brand broader reach across inflammatory conditions and strengthening AbbVie’s presence in gastroenterology and rheumatology.

Everyday handling and patient experience

Most patients receive Skyrizi via a pre-filled syringe or injection kit, typically in a clinic setting, though self-injection is also used in some markets. The device is designed with a relatively thick grip and a clear viewing window so nurses can see the plunger glide smoothly as the dose is delivered.

On the skin, many users describe a short sting and a subtle pressure, then nothing more than a small redness that fades. For people who spent years hiding elbows and knees under long sleeves, the feeling of pulling on a T-shirt without checking plaques first is often a quiet but convincing milestone.

Pricing and availability

In the United States, Skyrizi is available by prescription and reimbursed under many commercial and public insurance plans, with list prices in the high four-figure dollar range per dose, depending on formulation and indication. AbbVie offers patient assistance and co-pay support programs to reduce out-of-pocket costs for eligible users.

In Europe, Skyrizi is marketed via AbbVie’s international network with country-specific reimbursement decisions, often tied to demonstrated cost-effectiveness versus established biologics. German regulators and other EU bodies have assessed IL-23 inhibitors within broader psoriasis treatment guidelines, placing them as options after conventional systemic therapies.

Safety profile and monitoring

Like other biologic immunomodulators, Skyrizi carries warnings related to infection risk and requires screening for tuberculosis before treatment. Regular follow-up visits help clinicians track skin response, adverse events and, where relevant, involvement of joints or the gut.

Clinical data and post-marketing surveillance have not flagged unexpected safety issues beyond the class profile, though rare serious infections and hypersensitivity reactions are reported and must be watched carefully. For many patients and physicians, the balance between efficacy and manageable risks is what keeps Skyrizi in the conversation.

Company context and shares

AbbVie built Skyrizi on years of immunology experience and has made it a centrepiece of presentations to analysts as it reshapes its portfolio around newer biologics. The AbbVie share price (ISIN US00287Y1091) trades on the NYSE in US dollars, recently near the mid-250s according to market data.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | US00287Y1091 | ABBVIE INC. | boerse | 69650425 | bgmi